Finland· FI-REL-REL5914

Visine

A tetryzoline product, registered in Finland by Pfizer Service Company BVBA. The same ATC class is registered in 6 of our 19 countries.

ATC S01GA02

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedVisineATCS01GA02REGISTER NO.FI-REL-REL5914PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Tetryzoline is registered in 6 of 19 countries.

Countries holding a registration under ATC S01GA02 (tetryzoline), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 5 of them publish a price we can compare per daily dose

Tetryzoline · ATC S01GA02

6 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Manufacturer
Pfizer Service Company BVBA
Country
Finland (FI)
ATC code
S01GA02
ATC class
Tetryzoline
Defined daily dose
62.5 mcg, AT
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

53 interactions on record for tetryzoline.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tetryzoline · interactions on record

53 records

  • 7 severe
  • 46 moderate

Most severe, free to view

  • MethylergometrineG02AB01severe
  • ErgometrineG02AB03severe
  • DihydroergotamineN02CA01severe
  • ErgotamineN02CA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0e4c77ef-ac7f-4419-96eb-b2af178c5cc3
GET /v1/drugs/0e4c77ef-ac7f-4419-96eb-b2af178c5cc3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "silmätipat",
  "route": null,
  "ddd_unit": null,
  "strength": "0.5 mg/ml",
  "atc_label": "tetrytsoliini",
  "ma_number": "4092",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL5914",
  "authorised_at": "1966-09-21"
}

See everything about tetryzoline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.